The G7 Research Group at the Munk School of Global Affairs at Trinity College in the University of Toronto presents the

2015 Schloss Elmau G7 Summit Final Compliance Report
9 June 2015 to 6 May 2016

Prepared by
Michael Humeniuk, Jerome Newton, Christian Medeiros and Kaleem Hawa
with Caroline Bracht
G7 Research Group, University of Toronto

23 May 2016
www.g7.utoronto.ca
g8@utoronto.ca
@g7_rg and @g8rg

“We have meanwhile set up a process and there are also independent institutions monitoring which objectives of our G7 meetings we actually achieve. When it comes to these goals we have a compliance rate of about 80%, according to the University of Toronto. Germany, with its 87%, comes off pretty well. That means that next year too, under the Japanese G7 presidency, we are going to check where we stand in comparison to what we have discussed with each other now. So a lot of what we have resolved to do here together is something that we are going to have to work very hard at over the next few months. But I think that it has become apparent that we, as the G7, want to assume responsibility far beyond the prosperity in our own countries. That’s why today’s outreach meetings, that is the meetings with our guests, were also of great importance.”

Chancellor Angela Merkel, Schloss Elmau, 8 June 2015
Contents

Preface .......................................................................................................................... 3
  Research Team .......................................................................................................... 4
  Analysts ...................................................................................................................... 4
Executive Summary ................................................................................................... 5
  The Final Compliance Score .................................................................................. 5
  Compliance by Member ............................................................................................ 5
  Compliance by Commitment .................................................................................... 5
  The Compliance Gap Between Members ................................................................ 5
Future Research and Reports ..................................................................................... 5
  Table A: 2015 Priority Commitments Selected for Assessment ......................... 6
  Table B: 2015 G7 Schloss Elmau Final Compliance Scores .................................... 8
  Table C: 2015 G7 Schloss Elmau Final Compliance Scores by Country ............... 9
  Table D: 2015 G7 Schloss Elmau Final Compliance Scores by Commitment ....... 10
1. Macroeconomic Policy: Foster Growth ................................................................. 11
2. Macroeconomic Policy: Fiscal Flexibility ............................................................. 19
3. Infrastructure: Infrastructure Investment ............................................................... 31
4. Gender: Supporting Women Entrepreneurs ......................................................... 39
5. Financial Regulation: Automatic Exchange of Tax Information ....................... 47
6. Financial Regulation: Tax Agenda ........................................................................ 53
7. Terrorism: Terrorists’ Assets ................................................................................ 61
8. Nonproliferation: Arms Trade .............................................................................. 70
9. Regional Security: Ukraine .................................................................................... 76
10. Regional Security: Maritime ................................................................................ 84
11. Human Rights: Migrants ....................................................................................... 94
12. Development: Refugee Crisis .............................................................................. 103
13. Health: Coordinated Rapid Deployment ............................................................. 135
15. Health: Vaccines .................................................................................................. 155
16. Climate Change: Growth Agenda ....................................................................... 163
17. Climate Change: Low-Carbon Strategies ............................................................ 172
18. Climate Change: Copenhagen Accord .................................................................. 183
19. Climate Change: Vulnerable Countries ............................................................... 192
20. Energy: Liberalizing Systems ............................................................................... 203

“[We will] effectively implement our national action plans.”

*G7 Schloss Elmau Summit Declaration*

Assessment

<table>
<thead>
<tr>
<th></th>
<th>Lack of Compliance</th>
<th>Work in Progress</th>
<th>Full Compliance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Canada</td>
<td></td>
<td>+1</td>
<td></td>
</tr>
<tr>
<td>France</td>
<td></td>
<td>+1</td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td></td>
<td>+1</td>
<td></td>
</tr>
<tr>
<td>Italy</td>
<td></td>
<td>–1</td>
<td></td>
</tr>
<tr>
<td>Japan</td>
<td></td>
<td></td>
<td>+1</td>
</tr>
<tr>
<td>United Kingdom</td>
<td></td>
<td></td>
<td>+1</td>
</tr>
<tr>
<td>United States</td>
<td></td>
<td></td>
<td>+1</td>
</tr>
<tr>
<td>European Union</td>
<td></td>
<td></td>
<td>+1</td>
</tr>
<tr>
<td>Average</td>
<td></td>
<td></td>
<td>+0.75</td>
</tr>
</tbody>
</table>

Background

Antimicrobial therapies (AMTs) are a vital part of medical research and progress for both humans and animals that involve the use of antimicrobial medicines such as antibiotics to prevent and stop infection. Antimicrobial resistance (AMR) is the resistance of microorganisms to antimicrobials and is a natural process that arose with the usage of AMTs.

Recently there has been a surge in AMR in G7 members due to a variety of factors including overuse of antimicrobial medicines and improper control protocol. This has directly caused significant health issues to animals and humans. AMR patients have a risk of death three times higher than the average infected patient, and are more likely to acquire complications, putting a burden on healthcare systems and their finances.

The European Commission has since made AMR control and reduction a high priority. In 2011 it created the action plan against the rising threats from AMR, identifying 12 important actions including “preventing microbial infections” and “improved monitoring and surveillance in human and animal medicine.”

The G7 members claim they “fully support” the World Health Organization’s (WHO) Global Action Plan on Antimicrobial Resistance since the plan’s creation at the World Health Assembly in May 2015. The leaders state that they will “effectively implement our national action plans and support other countries as they develop their own national action plans.” This incorporates the strategies of the Joint Efforts to Combat Antimicrobial Resistance. One Health, an approach that combines environmental, agricultural, human and
animal health perspectives and sectors, also guides all the national action plans. These commitments are consistent with the contents of the 2015 Elmau Summit Annex of the Leaders’ Declaration.

**Commitment Features**

The commitment brings forward the WHO Global Action Plan, under the framework and guidelines of One Health, supplemented by the Joint Efforts to Combat Antimicrobial Resistance (JECAR). Although One Health and the JECAR include many subsidiary goals, progress towards these goals does not count as compliance. Rather, the inclusion of measures to combat AMR within a national action plan is the metric used for compliance.

There is specific mention by the leaders in the commitment of the implementation of “our national plans.” The annex to the Leaders’ Declaration also clearly states the support of the G7 members to the WHO Global Action Plan, and the objectives within. This suggests the approach of the G7 members to deal with Antimicrobial Resistance is by creating a national plan that follows the requirements of the WHO Global Action Plan on Antimicrobial Resistance in their respective countries. By fulfilling the objectives of the WHO Global Action Plan through national plans, G7 members indicate full compliance.

The five objectives present in the WHO Action Plan to be followed in the national plans are to reduce incidence of infection, improve awareness and understanding, carry out further surveillance and research, use AMTs efficiently, and create sustainable investment on a global scale. Therefore measures falling within the WHO objectives range, such as prevention or surveillance, must relate specifically to antimicrobial resistances. For example, a program that ends up reducing infection incidence through improved sanitation does not constitute compliance unless the program was specifically addressing antimicrobial resistances through program partners and the government.

Partial compliance constitutes a program or policy which is specified to address antimicrobial resistances, however, does not pertain to the WHO Global Action Plan.

Collaboration between various actors and sectors, such as increased professional communication between veterinarians and physicians also satisfies the commitment if the interactions purpose is related to antimicrobial resistances. Connections between different actors, as a part of the One Health approach, should be viewed as an additional objective as it underlies the WHO Global Action Plan, and G7 leaders have “strongly committed” to the approach.

---

### Scoring Guidelines

<table>
<thead>
<tr>
<th>Score</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>-1</td>
<td>Member introduces no new measures or programs to address antimicrobial resistance AND does not act to further the support or implementation of the WHO Global Action Plan on Antimicrobial Resistance.</td>
</tr>
<tr>
<td>0</td>
<td>Member introduces new measures or programs to address antimicrobial resistance BUT does not act to further the support or implementation of the WHO Global Action Plan on Antimicrobial Resistance.</td>
</tr>
<tr>
<td>+1</td>
<td>Member acts to further the support or implementation of the WHO Global Action Plan on Antimicrobial Resistances AND introduces new measures to address antimicrobial resistance.</td>
</tr>
</tbody>
</table>

**Canada: +1**

Canada has fully complied with its commitment to further the support of the World Health Organization (WHO) Global Action Plan on Antimicrobial Resistance (AMR).

Minister of Health Jane Philpott announced on 19 November 2015 that “in 2016, Canada will provide additional funding to the Canadian Institutes of Health Research to further study AMR.”

She also commended Canada’s progress on surveillance and its dedication to spreading awareness of AMR.

The Public Health Agency of Canada participated in Antibiotic Awareness Week from 18 November 2015 to 22 November 2015 by partnering with Antibiotic Awareness, a website dedicated to informing health care providers and the general public about the dangers of antibiotic resistance.

Although Canada has not introduced new, major measures to address antimicrobial resistances, the government continues to implement its Federal Action Plan on Antimicrobial Resistance and Use in Canada, which focuses on surveillance, stewardship, and innovation to curtail the threat of antimicrobial resistance. This is a clear demonstration of Canada’s support of the WHO Global Action Plan on Antimicrobial Resistance.

Canada receives a compliance score of +1 for announcing additional funding to study AMR and for continuing to spread awareness of AMR.

**Analyst: Doris Li**

**France: +1**

France has fully complied with its commitment to further the support of the World Health Organization (WHO) Global Action Plan on Antimicrobial Resistance (AMR).

On 23 September 2015, Minister of Social Affairs and Health Marisol Touraine stressed the importance of innovation and the coordination of efforts. She therefore announced the launch of a plan for national interdisciplinary research on antimicrobial resistance in 2016, which will be a joint effort between the Alliance

---


for Life Sciences and Health (AVIESAN) and the National Alliance Research for the Environment (AllEnvie).\textsuperscript{897}

Marisol Touraine also plans to rely on “new technologies and social networks” to raise awareness about antimicrobial resistance. On 23 September 2015, she announced her support for le LIEN and AC2BMR’s campaign to promote awareness about AMR to civil society and her intent on bringing it to the attention of the Prime Minister.\textsuperscript{898}

On 30 October 2015 at a symposium organized by the National Authority of Health, Marisol Touraine urged for the proper use of medicine considering the dangers of AMR.\textsuperscript{899}

On 17 November 2015, France and the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) organized an Intergovernmental Workshop to discuss ways to improve programs meant to combat AMR.\textsuperscript{900}

On 18 November 2015, France continued its support for European Antibiotic Awareness Day through its yearly campaign designed to reduce use of antibiotics and also participated in the first World Antibiotic Awareness Week.\textsuperscript{901}

Therefore, France receives a compliance score of +1 for its new initiatives to further the support of the WHO Global Action Plan on Antimicrobial Resistance.

\textit{Analyst: Doris Li}

\textbf{Germany: +1}

Germany has fully complied with the commitment made at the Schloss Elmau Summit in June 2015 to “pool … national efforts in order to share best practices and promote the prudent use of antimicrobials among all relevant stakeholders.”\textsuperscript{902}

The German government and the German Federal Health Ministry are strongly committed to further support the World Health Organization (WHO) Global Action Plan on Antimicrobial Resistance (AMR). Germany is also committed to the “One Health” approach, which is emphasized in several reports and initiatives in its fight with AMR plans.\textsuperscript{903,904} As proposed by the WHO Action Plan, Germany has put together strategies to

“reduce incidence of infection,” “improve awareness and understanding,” “further surveillance and research,” “efficiently use [antimicrobial therapies],” “create sustainable investment on a global scale.”

The German government and other public and private enterprises have launched several projects that comply with the WHO Action Plan and strengthen Germany’s One Health approach. The GERMAP report, the RESET project, and the Med Vet-Staph project are all listed as examples of best practices by Germany in the first edition of the “Combating Antimicrobial Resistance report,” published in September 2015.

In September 2015, the Organisation for Economic Co-operation and Development published a report entitled “Antimicrobial Resistance in G7 Countries and Beyond: Economic Issues, Policies and Option for Action,” in which Germany’s efforts are listed and detailed. According to this report, Germany’s efforts thus far to implement, and strengthen already existing policies concerning antimicrobial resistance fully comply with the Elmau 2015 commitments. Included are several of Germany’s objectives to uphold its commitments such as “Improve feedback on antibiotic use data; develop guidelines on use & communication between doctor & patient,” “disrupt infection cycles and avoid infections.” “Strengthen one-health initiative at national and international level,” “promote awareness; strengthen [education] capacities,” “establish AMR online platform for HPs; strengthen [sic] tr on hygiene; incorporate AMR into clinical trials.”

Therefore, Germany has been awarded a score of +1 for its full compliance on AMR, its support for the One-Health approach and commitment to the WHO Action Plan.

Analyst: Camille Beaudoin

Italy: −1

Italy has not complied with its health commitment to further support to the World Health Organization (WHO) Global Action Plan on Antimicrobial Resistance.

Although Italy has supported key objectives of the WHO Action Plan and made efforts to support the One Health approach, it has made no substantive effort to expand this implementation since the 2015 Elmau Summit.

Therefore, Italy receives a compliance score of −1.

Analyst: Camille Beaudoin

Japan: +1

Japan has fully complied with the commitment to strengthen the World Health Organization (WHO) Global Action Plan on Antimicrobial Resistance (AMR). For many years, Japan has provided a constant reassurance on the importance of communicable diseases and AMR.

In a statement published on 12 December 2015, the Office of the Prime Minister of Japan reiterates the significance of adhering to the “One Health Approach” along with other G7 members to fight against AMR.

---

The Prime Minister’s Office states that due to the increase of globalization, notably in the Asia Pacific region, Japan’s geographical locality makes it more responsible for addressing the issue of AMR.910 As of 19 October 2015, the Joint Programming on Antimicrobial Resistance (JPIAMR) voted in Japan as its newest member, which will be represented by AMED.911 This is a crucial step forward as the JPIAMR now includes all residing members of the G7, allowing for closer collaboration and adherence to WHO guidelines. Thus, Japan is awarded a +1 in terms of compliance.

**United Kingdom: +1**

The United Kingdom has fully complied with the commitment to strengthen the World Health Organization (WHO) Global Action Plan on Antimicrobial Resistance (AMR).

The UK Department of Health released a Five Year Antimicrobial Strategy (2013–2018) to address the growing concern and challenges of AMR.912 In particular, the strategy seeks to address the detailed initiatives by the Annual Chief Medical Officers Report in 2011, in accordance with the One Health approach.913 The plan set forth by the United Kingdom addresses concerns stipulated in the WHO Action Plan. The report indicates that the strategy to slow the development of AMR is by properly managing and conserving the effectiveness of existing treatment, improving the knowledge and understanding of AMR, and to stimulate new treatment methods, antibiotics and diagnostics.914 It employs the WHO Action Plan by identifying seven key areas for future action.

On 23 October 2015, the UK Department of Health released a progress report on its Five Year Strategy. The UK committed to increasing collaboration with the WHO further and to making progress in preparation for a “high-level AMR meeting at the [UN General Assembly] in 2016.”915

As of the end of 2015, the National Institute for Health Research (NIHR) has invested of GBP15.8 million in 16 studies, with more to be launched in 2016 and beyond.916

Thus, the United Kingdom has been awarded a +1 for acting to further implement the WHO Global Action Plan on Microbial Resistances by creating and installing a national plan.

**Analyst: Garrett Hajnal**

**United States: +1**

The United States has fully complied with the commitment to strengthen the World Health Organization (WHO) Global Action Plan on Antimicrobial Resistance (AMR). The United States has acted both to further the support of and implement the WHO Global Action Plan.

On 28 July 2015, the White House released a Fact Sheet on the Global Health Security Agenda (GHSA). The fact sheet states that the GHSA “empowers countries, international organizations and civil society to work together to achieve focused goals,” such as “countering antimicrobial resistance … [and] strengthening real-time biosurveillance.”917 The State Department has integrated AMRs into negotiations regarding binding international Science and Technology Agreements.918

In October 2015, the Biomedical Advanced Research and Development Authority (BARDA) released solicitation for “white papers and proposals for funding to develop diagnostics to identify and inform treatment of antimicrobial-resistant bacterial infections.”919 In November 2015, BARDA was “in contract negotiations to support development of their first AMR diagnostic platform and assay.”920 The Department of Health and Human Services claims these initiatives will make AMR-detection quicker and more accurate.921

In November 2015, the Taskforce for Combating Antibiotic-Resistant Bacteria released the National Action Plan for Combating Antibiotic-Resistant Bacteria: First 180 Days Report.922 The report is an update to the initial action plan released in March 2015, and provides details of initiatives taken to ensure that the five goals outlined in the report are met.923

According to the First 180 Days Report, antibiotic stewardship initiatives “continue to be introduced and evaluated” in both human health and animal health contexts.924 On 2 June 2015, the White House hosted a one-health antibiotic stewardship forum to connect human health and animal health stakeholders to combat AMR.925

The First 180 Days Report also claims that the United States government plans to “expand laboratory capacity to detect and track antibiotic resistance, and to improve surveillance data integration.”926 The report also mentions other developments in AMR research and surveillance, including 1) the creation of a joint CDC and FDA antibiotic-resistant isolate bank; 2) multiple USG departments’ awarding of projects to

discover “new antibacterial products and alternatives to antibiotics in animals and humans”; and 3) greater surveillance of AMR through retail meat testing.  

Thus, the United States has fully complied with the commitment on AMR and received the score of +1.

*Analyst: Raajan Aery*

**European Union: +1**

The European Union has fully complied with the commitment to strengthen the World Health Organization (WHO) Global Action Plan on Antimicrobial Resistance (AMR). The European Union has acted both to further support and to implement the WHO Global Action Plan.

In August 2015, the European Commission sent out a questionnaire regarding the “distribution and use of antimicrobial veterinary medicinal products” to all EU members, the Advisory Group on the Food Chain and Animal and Plant Health members, and the Food and Veterinary Office. The questionnaire will be followed up by fact-finding missions in 2016 and an overview report scheduled for 2017.

In September 2015, the Innovative Medicine Initiative, a public-private partnership between the European Commission and the pharmaceutical industry, launched its sixth call for proposals to “re-activate research and development by Industry for new antibiotics and related issues.”

From 22 to 23 October 2015, the Transatlantic Taskforce for Antimicrobial Resistance (TATFAR), which is made up of members from the United States, EU and Sweden, held a face-to-face meeting to “review progress and discuss follow-up.” The talks resulted in a TATFAR Work Plan for 2016-2020 that is expected to be adopted in the first quarter of 2016.

On 16 November 2015, the European Commission released the Road Map for the Action Plan against the Rising Threats from Antimicrobial Resistance. The action plan focuses efforts on the following: 1) appropriate use of antimicrobials; 2) prevent microbial infections and their spread; 3) develop new effective antimicrobials or alternatives for treatment; 4) joining forces with international partners to contain the risks of spreading AMR from international trade and travel and via the environment; 5) monitoring and surveillance; 6) additional research and innovation; and 7) communication, education and training.

On 18 November 2015, the European Centre for Disease Prevention and Control continued to use European Antibiotic Awareness Day to “raise awareness about [AMR],” which has “developed into a platform of global reach.”

---

The European Commission is working to expand animal health legislation to emphasize preventive health measures.\textsuperscript{936} The legislation is expected to be published in the Official Journal in May 2016.\textsuperscript{937}

Thus, the EU has received a score of +1.

\textit{Analyst: Jerome Newton}